Skip to main content
Wholesale Pricing for Licensed Professionals

Myopia management · Practice playbook

Adding Myopia Management for the kids already in your chairs.

Turn the visit where a child's prescription jumps into a measured, multi-year program with a clear fee.

Pediatric ophthalmologist, optometrist and technician planning a children's myopia program at a clinic counter

Quick answer

Start with the myopic kids you already see.

Pick the treatments your doctors and staff can deliver, buy or borrow a way to measure, write a program fee and a consent form, and offer it to every child whose prescription changed this year. MD and OD practices follow the same steps.

Key takeaways

  • The FDA cites the National Eye Institute: myopia affects about 40% of the US population.
  • Four treatment families now have trial evidence: soft lenses, ortho-k, spectacle designs and low-dose atropine.
  • MiSight (ages 8 to 12) and Stellest (ages 6 to 12) carry FDA myopia-control indications.
  • Revenue comes from a program fee, materials, the optical and scheduled visits, in ophthalmology and optometry practices alike.
  • Contact lenses and Rx are excluded from the 15% participation credit.

A six-step launch.

Each step fits inside a normal clinic schedule.

The treatment menu.

Labeled status and evidence as of October 2026, listed without ranking. The doctor and the family choose; many practices offer more than one, and some refer between pediatric ophthalmology and optometry.

CooperVision logo Essilor logo Euclid Systems logo Paragon CRT (CooperVision) logo
Option US status Evidence highlight Who typically provides
MiSight 1 day soft lens FDA approved 2019, ages 8 to 12 at start 59% slower refractive progression over 3 years vs single vision Optometrists and ophthalmologists certified to fit it
Stellest spectacle lens FDA De Novo authorization 2025, ages 6 to 12 at start 71% less refractive progression at 24 months Prescribed by ODs and MDs; dispensed by the optical
Ortho-k Approved for temporary myopia reduction; myopia control off-label 43% slower axial elongation over 2 years (ROMIO) Ortho-k trained optometrists and ophthalmologists
Low-dose atropine No FDA-approved product; compounded and off-label 0.01% beat placebo over 3 years (CHAMP) Pediatric ophthalmologists, ophthalmologists and optometrists, within state scope
Soft multifocals Myopia control is off-label +2.50 add slowed progression 0.46 D over 3 years (BLINK) Optometrists and ophthalmologists who fit contact lenses
Practice pearl

Show parents the axial length curve at every visit. A family that sees the line flatten keeps coming back, and that recall is what sustains the service.

Frequently asked questions

Do I need expensive equipment to start?

No. Cycloplegic refraction and a contact lens fitting set are enough to begin. Add a biometer and topographer as volume grows.

Which treatment should I offer first?

Vision Rescue does not rank them. Practices often begin with whatever fits their current workflow: an optical for spectacle designs, a contact lens service for soft lenses or ortho-k, or prescribing for atropine.

How do I explain off-label options?

Use a written consent that states the option is not FDA labeled for myopia control and why you recommend it.

Is this for ophthalmology or optometry practices?

Both. Pediatric and comprehensive ophthalmologists and optometrists run myopia programs; the launch steps, consent and fee structure are the same, and scope of practice varies by state.

How is the service paid for?

Mostly through a self-pay program fee plus materials. The coding guide covers common models.

Does the participation credit apply here?

Only to eligible OTC items such as GP care solutions ordered on VisionRescue.com through RescueLink. Contact lenses and Rx are excluded.

References

  • US FDA. FDA authorizes marketing of first eyeglass lenses to slow progression of pediatric myopia. September 25, 2025. FDA
  • Lawrenson JG, Huntjens B, Virgili G, et al. Interventions for myopia control in children: a living systematic review and network meta-analysis. Cochrane Database Syst Rev. 2025;2:CD014758. PubMed
  • Wolffsohn JS, Whayeb Y, Logan NS, et al. IMI global trends in myopia management attitudes and strategies in clinical practice, 2022 update. Invest Ophthalmol Vis Sci. 2023;64(6):6. PubMed

About this guide

Written for licensed eye care practices by the Vision Rescue team. Questions: providers@visionrescue.com or 1-855-692-8024.

Important notes and disclosures

This page is not billing, coding or legal advice. Codes, coverage and plan rules vary by payer and state and change over time. Confirm with your billing team and each payer.

Turn the stronger prescription into a plan.

Equip the practice from the wholesale catalog and send families the care products they need through RescueLink.

Stay current: Latest eye care industry news